Olympus (TYO:7733) announced today that it entered into a strategic distribution agreement with EndoClot Plus.
EndoClot Plus develops technologies in the hemostasis space, including the EndoClot PHS — a nonthermal, nontraumatic method for achieving hemostasis with GI bleeds designed to help gastroenterologists stop bleeding rapidly and reliably.
The biomaterial therapeutic solution developer is based in Santa Clara, California and has operations in Suzhou, China, according to a news release.
“We are very excited to partner with a market-leading company in bringing our breakthrough technologies to market,” EndoClot Plus President Stephen Heniges said in the release. “With Olympus behind our solutions, we expect that market penetration will be swift, and the real winners will be GI healthcare providers and their patients.”
Center Valley, Pennsylvania-based Olympus said that the EndoClot Plus technologies complement its GI endoscopy portfolios and its overall medtech strategy. The addition of EndoClot Plus’ offerings to Olympus’ portfolio supports procedures for the endoscopic removal of polyps, adenomas, early-stage cancers and other gastrointestinal mucosal lesions.
“GI hemostasis continues to be an area of focus for the GI EndoTherapy Business Unit,” Olympus of the Americas Global VP and GM of EndoTherapy Mike Callaghan said. “The EndoClot partnership reinforces our commitment to broaden our portfolio with clinically differentiated technologies that we can offer to our customers who treat patients with GI bleed disorders. I’m pleased that together with EndoClot, we will usher in a new standard of care in GI.”
